Key result
Case report describes Impella 5.5-assisted 4-vessel CABG in a patient with LVEF <20% and persistent VT.
Why the study?
No research has evaluated Impella 5.5 use in patients with left ventricular ejection fraction under 20% and persistent nonsustaining ventricular tachycardia.
Case Report (n=1)
Answers are grounded in this paper and cite their sources.
This case report highlights the potential use of Impella 5.5 for perioperative mechanical circulatory support during CABG in high-risk patients with severely reduced LVEF and postoperative arrhythmias.
Coronary artery disease is the most common type of heart disease. Revascularization with coronary artery bypass grafting can improve survival in patients with severe coronary artery disease and reduced left ventricular ejection fraction. The Impella 5.5 (Abiomed) with SmartAssist intravascular microaxial blood pump can provide safe and effective perioperative support in patients with severely reduced left ventricular ejection fraction of less than 20%. However, no research has been conducted on Impella 5.5 use with patients who have left ventricular ejection fraction of less than 20% and persistent nonsustaining ventricular tachycardia. More research is needed on the use of the Impella device, specifically regarding patient profile, timing, and device management. This case report describes the outcomes of a 4-vessel coronary artery bypass grafting revascularization procedure assisted by Impella use and dobutamine in combination with antiarrhythmic agents for a patient with both severe coronary disease and persistent nonsustaining ventricular tachycardia postoperatively.
No takes yet. Share an insight, caveat, or question.
Hong Zhao (2026) conducted a case report in Severe coronary artery disease with left ventricular ejection fraction <20% and persistent nonsustaining ventricular tachycardia (n=1). Impella 5.5-assisted 4-vessel coronary artery bypass grafting with dobutamine and antiarrhythmic agents was evaluated on Procedural and postoperative outcomes. Impella 5.5-assisted 4-vessel CABG was described in 1 patient with severe coronary disease, LVEF <20%, and persistent nonsustaining ventricular tachycardia.
Synapse has enriched 10 related papers. Consider them for comparative context: